Boundless Bio Inc
BOLD
NASDAQ
Biotechnology
$2.83
USD
+0.06 (+1.98%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $63.38M
Volume 109.0K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-64.01M
TTM
+0.6%
YoY
Operating Cash Flow
$-56.25M
TTM
-1.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.8 | 4.5 | 4.2 | 4.7 | 10.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 17.1 | 15.1 | 14.0 | 14.5 | 24.4 |
Operating Income | -17.1 | -15.1 | -14.0 | -14.5 | -24.4 |
EBITDA | -16.7 | -14.8 | -13.7 | -14.2 | -23.1 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 1.4 | 1.3 | 1.1 | 0.9 | 0.7 |
Income Before Income Taxes | -15.7 | -13.9 | -12.9 | -13.6 | -23.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -15.7 | -13.9 | -12.9 | -13.6 | -23.7 |
Consolidated Net Income / Loss | -15.7 | -13.9 | -12.9 | -13.6 | -23.7 |
Net Income Attributable to Common Shareholders | -15.7 | -13.9 | -12.9 | -13.6 | -23.7 |
Basic EPS | -$0.70 | -$0.62 | -$0.58 | -$0.60 | -$1.06 |
Diluted EPS | -$0.70 | -$0.62 | -$0.58 | -$0.60 | -$1.06 |
Basic Shares Outstanding | 22.4M | 22.4M | 22.4M | 22.4M | 22.5M |
Diluted Shares Outstanding | 22.4M | 22.4M | 22.4M | 22.4M | 22.5M |